---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-015881"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2025-04-28T23:59:59+00:00"
generated_at: "2026-05-23T04:49:35.044271+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics receives FDA approval for yield enhancement process; expects ~20% output increase

## Summary
- FDA approved innovative production yield enhancement process increasing yields by ~20% from same plasma volume.
- Approval applies to both immune globulin products ASCENIV and BIVIGAM.
- CEO anticipates revenue and earnings acceleration beginning late 2025 and accelerating into 2026.
- First U.S. regulatory approval for such a process; highlights ADMA's internal R&D and capital efficiency.

## SEC filing metadata
- accession: 0001140361-25-015881
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2025-04-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036125015881/0001140361-25-015881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036125015881/ef20048038_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-015881
- JSON: https://secwatch.observer/filing/0001140361-25-015881.json
- Plain text: https://secwatch.observer/filing/0001140361-25-015881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.